A vesicle just 30–150 nm across, released by cells to carry repair signals to their neighbours.
Exosomes are nanoscale extracellular vesicles, roughly 30 to 150 nm in diameter, released by almost every cell type. Wrapped in a lipid bilayer, they carry a concentrated cargo of proteins, mRNA, miRNA and lipids, and they travel between cells to deliver instructions. In effect they are the body's own courier system: a vesicle shed by one cell is taken up by another, and its cargo changes how the recipient behaves.
Exosomes derived from mesenchymal stem cells (MSCs) inherit much of the reparative activity of their parent cells while setting aside most of the risk. They carry no nucleus and do not divide, so the concerns that accompany whole-cell therapy — immune rejection, embolisation, unwanted engraftment — largely do not apply. This is why the field increasingly refers to MSC-derived exosomes as cell-free stem cell therapy.
JuvGuard delivers that cargo as a nebulized mist. The inhaled droplets settle directly onto the airway and alveolar surface, releasing the vesicles where the injury actually sits rather than asking the systemic circulation to find it.
From targeted delivery through to anti-fibrotic remodelling, four stages that act in sequence on lung injury.
Surface integrins and tetraspanins help the vesicles recognise injured alveolar epithelial cells and fibroblasts. Inhaled as a mist, they reach the distal airways first instead of circulating through the whole body.
Exosomal miRNA such as miR-146a and miR-21 has been shown to lower IL-6 and TNF-α while raising IL-10, and to shift macrophages from an M1 toward an M2 phenotype — restoring a calmer immune environment in the lung.
More than 450 growth factors, miRNAs and proteins engage resident progenitor cells, supporting the proliferation, migration and differentiation of alveolar epithelial and endothelial cells so damaged tissue can rebuild.
Suppression of the TGF-β/Smad pathway reduces myofibroblast differentiation and collagen deposition while favouring matrix remodelling — the step most directly tied to fibrosis progression.
The same four stages, described at molecular level, for clinicians and researchers.
The exosomal surface presents integrins together with the tetraspanins CD9, CD63 and CD81, and carries the CD47 "don't eat me" signal that helps vesicles evade macrophage clearance and persist longer in lung tissue. Nebulized delivery builds a high local concentration at the alveolar surface before clearance begins, which is precisely why the inhaled route is attracting attention in lung disease.
Chronic lung disease usually involves persistent low-grade inflammation. Exosomal cargo acts on inflammatory cascades including NF-κB, lowering IL-6 and TNF-α while lifting IL-10 and reparative mediators, and influences M1/M2 macrophage polarisation as well as regulatory T-cell proportions — moving the microenvironment from inflammation toward repair.
Growth factors and angiogenesis-related miRNA support the proliferation of type II alveolar epithelial cells and their differentiation into type I cells, encouraging surfactant production, while also supporting repair of the pulmonary capillary endothelium and improving ventilation-perfusion matching — findings consistent with the paired gains in forced vital capacity and six-minute walk distance seen in the trial.
The TGF-β/Smad pathway is the central driver of fibroblast-to-myofibroblast transition. Exosomal cargo inhibits Smad2/3 phosphorylation, down-regulates α-SMA and type I collagen expression, and raises matrix metalloproteinase activity, encouraging degradation and remodelling of matrix already laid down — thereby slowing the fibrotic process.
The same vesicles, two different routes — and the route determines both lung concentration and long-term adherence.
| Dimension | Nebulized Inhalation (JuvGuard) |
Intravenous Infusion |
|---|---|---|
| Route of administration | Inhaled through a nebuliser; deposited by normal breathing | Delivered through a vein |
| Invasiveness | Needle-free; no venous access required | Requires venous access |
| Local concentration in the lung | High — deposited directly on the airway and alveolar surface | Lower — diluted through the systemic circulation, with much of the dose retained by liver and spleen |
| Systemic exposure | Low | High |
| Patient adherence | High — a session lasts minutes and is easy to sustain | Lower — each session takes hours and must be given in a facility |
| Typical setting | Outpatient clinic or at home | Hospital or infusion centre |
| Tolerability | No serious adverse events in the Phase II trial | Infusion-related reactions are reported |
| Suitability for long-term support | Well suited to repeated courses over time | Usually reserved for inpatient or acute protocols |
Both routes have their place; the choice should follow a physician's judgement of the individual case.
The study below was carried out and published by an independent research team within the Nature portfolio. We cite the published record only and are not affiliated with, endorsed by or sponsored by the researchers or their institution.
Twenty-four participants with moderate-to-severe idiopathic pulmonary fibrosis, randomized double-blind against placebo, with 12 weeks of nebulized treatment followed by 24 weeks of follow-up.
Forced vital capacity rose by 12.5% (p < 0.01) and six-minute walk distance by 45 m (p < 0.05). HRCT fibrosis scores fell, and 83.3% of participants were recorded as responders.
No serious adverse events were observed and no immune rejection was recorded; nebulized administration was well tolerated throughout the treatment period.
These figures come from the published Phase II trial. Individual responses still vary, and they are not a promise of outcome for any one person.
Every day we search the international and Chinese core journals for new exosome and lung research. Below are the latest additions, each with a DOI link to the original paper.
Journal of extracellular vesicles · 2026
Pneumolysin is a pore-forming toxin made by Streptococcus pneumoniae, the bacterium behind most childhood pneumonia. At doses too low to burst a cell outright, host cells respond by patching their membranes and shedding vesicles that carry the toxin
Frontiers in immunology · 2026
Researchers isolated exosomes from adipose-derived mesenchymal stem cells and tested them in a mouse model of lipopolysaccharide-induced acute lung injury. Treated animals kept a more intact alveolar architecture, with lower lung injury scores and le
Journal of cellular and molecular medicine · 2026
Periodontitis destroys the bone that anchors teeth, and current treatments struggle to rebuild it. This study packages human umbilical cord blood-derived exosomes into an injectable, light-curable hydrogel designed to release them slowly. The composi
Browse the full Research Library
The evidence base behind JuvGuard rests on two things: publicly published, peer-reviewed literature, and our own technology and manufacturing operations.
Exosome and nebulized-delivery studies published by this institution's team are among the literature sources cited on this page. We reference the published record only; there is no affiliation, partnership, sponsorship or endorsement between us and the university or its researchers.
Holds the Japan Patent Office grant covering the core nebulized exosome technology and oversees PIC/S GMP production, with every batch independently tested by SGS.
Operates the exosome isolation and characterisation laboratory in Hong Kong and coordinates investigator-initiated clinical observation with partner medical institutions.
A sales consultant can walk you through the data and help you judge whether JuvGuard fits your situation.
WhatsApp & phone: +852 6746 9492
You can also reach us at info@juvguard.com. JuvGuard is a health support product and is not a substitute for medicine.